First AD

Second AD

Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation

Melanoma & Skin Cancer

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma

Peer Exchange

For patients with BRAF-mutant metastatic melanoma, doctors assess symptoms and disease status to determine if they should start treatment with combination immunotherapy, or 8-12 weeks of BRAF/MEK targeted therapy before switching to immunotherapy, which offers the possibility of durable responses or cure.

The Role of Biomarker Testing in the Management of Metastatic Melanoma

Best Practices for Biomarker Testing in Metastatic Melanoma

Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma

Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma

Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma

Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma

Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases

Treatment Approaches For Patients With BRAF-Mutated Melanoma and Symptomatic Brain Metastases

Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

The Future of Metastatic and Unresectable Melanoma Treatment